Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0662 • ACR Convergence 2024
Deucravacitinib, a First-in-Class, Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in SLE: Efficacy by Baseline Demographics and Disease Characteristics in the Phase 2 PAISLEY Trial
Eric Morand¹, Cristina Arriens², Laura Geraldino³, Ann E. Clarke⁴, Samantha Pomponi⁵, Coburn Hobar⁵, Thomas Wegman⁶, Ravi Koti⁵, Subhashis Banerjee⁵ and Ronald Van Vollenhoven⁷, ¹School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia, ²Department of Arthritis and Clinical Immunology, Rheumatology, Oklahoma Medical Research Foundation and Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Division of Rheumatology, Department of Medicine, Columbia University, New York, NY, ⁴Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁵Bristol Myers Squibb, Princeton, NJ, ⁶Bristol Myers Squibb, Beaver Falls, PA, ⁷Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, Netherlands
Background/Purpose: Deucravacitinib is a first-in-class, oral, selective, allosteric tyrosine kinase (TYK2) inhibitor approved in multiple countries for the treatment of adults with moderate to severe…
Abstract Number: 0812 • ACR Convergence 2024
A Human Gut Pathobiont Drives Platelet Activation with Microparticle Release and NETosis During Lupus Nephritis Flares
Abhimanyu Amarnani¹, Cristobal Rivera-Martinez¹, Marc Scherlinger², Doua Azzouz¹, Andy Lee¹, Kate Trujillo¹, MacIntosh Cornwell¹, Tyler Weinstein¹, Tatiana Borja³, Bharati Matta⁴, Sharon Chung⁵, Laura Cooney⁶, Uzair Chaudhary¹, Steven Medvedovsky¹, Peter Izmirly¹, Jill Buyon¹, Patrick Blanco⁷, Betsy Barnes⁸, Bhama Ramkhelawon¹, Kelly Ruggles⁹ and Gregg Silverman¹, ¹New York University Grossman School of Medicine, New York, NY, ²Strasbourg University Hospital, Strasbourg, France, ³Feinstein Institutes for Medical Research, New York, NY, ⁴The Feinstein Institutes for Medical Research, Manhasset, NY, ⁵University of California, San Francisco and Immune Tolerance Network, San Francsico, ⁶University of Michigan and Immune Tolerance Network, Ann Arbor, MI, ⁷UMR_CNRS 5164 Immunoconcept, BORDEAUX CEDEX, France, ⁸Feinstein Institutes for Medical Science, Manhasset, NY, ⁹NYU Grossman School of Medicine, Brooklyn, NY
Background/Purpose: SLE is a leading cause of premature death, often from severe complications including lupus nephritis (LN), especially in disadvantaged groups. Despite advances in treatment,…
Abstract Number: 0910 • ACR Convergence 2024
Reduced Adenosine-Mediated Regulatory Activity Exacerbated by an NT5E Loss of Function Mutation Is Linked to Tissue Inflammation and Hypertension in Systemic Lupus Erythematosus
Katherine Owen¹, Isaac Peabody², Mikhail Olferiev³, Tyson Dawson², Prathyusha Bachali⁴, Peter Kasson⁵, Amrie Grammer⁶, Mary Crow³ and Peter Lipsky², ¹RILITE, Charlottesville, VA, ²Ampel Biosolutions, Charlottesville, VA, ³Hospital for Special Surgery, New York, NY, ⁴AMPEL BioSolutions, Redmond, WA, ⁵University of Virginia, Charlottesville, VA, ⁶AMPEL LLC, Charlottesville, VA
Background/Purpose: Adenosine is a purine nucleoside generated by the enzymatic activity of CD73/NT5E, that functions as an endogenous regulator of the immune system critical for…
Abstract Number: 1068 • ACR Convergence 2024
Improving Health Numeracy Literacy in Pediatric Patients with SLE
Nicole Salach¹, Sarah Rogal¹, Jessica Simpson¹, Sangeeta Sule², Abigail Bosk³ and Catherine Park¹, ¹Children's National Hospital, Washington DC, DC, ²Children's National Hospital, Washington, DC, ³Children's National Hospital, Bethesda, DC
Background/Purpose: Health literacy is key to better patient outcomes. One aspect of health literacy that warrants additional investigation in patients who have systemic lupus erythematosus…
Abstract Number: 1273 • ACR Convergence 2024
An Investigation of Traumatic Events and Mental Health in cSLE
Paris Moaf¹, Ashley Danguecan², Michelle Quilter³, Julie Couture⁴, Daniela Dominguez⁵, Lawrence Ng⁶, Asha Jeyanathan⁷, Reva Schachter⁸, Daphne Korczak⁹, Deborah Levy⁶, Linda Hiraki⁶ and Andrea Knight¹⁰, ¹The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ²The Hospital for Sick Children, Department of Psychology, University of Toronto, Toronto, ON, Canada, ³Whyteman’s Brae Hospital, Kirkcaldy, United Kingdom, ⁴Centre mère-enfant Soleil du CHU de Québec, Québec, Canada, ⁵The Hospital for Sick Children, Toronto, Canada, ⁶The Hospital for Sick Children, Toronto, ON, Canada, ⁷The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, The Hospital for Sick Children, Neurosciences and Mental Health, Research Institute, Toronto, ON, Canada, ⁸Sickkids Toronto, Toronto, ON, Canada, ⁹Hospital for Sick Children, University of toronto, Toronto, ON, Canada, ¹⁰Division of Rheumatology, The Hospital for Sick Children; Neurosciences and Mental Health, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with substantial morbidity, particularly in childhood-onset SLE (cSLE). Mental health conditions such as depression and…
Abstract Number: 1488 • ACR Convergence 2024
Clinical Utility and Performance of Anti-C1q Antibodies for Systemic Lupus Erythematosus: Comparative Analysis of Three Different Assays
Mariana Gonzalez-Trevino¹, MeLea Hetrick¹, Alain Sanchez-Rodriguez², Ali Duarte-Garcia¹ and Anne Tebo³, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic College of Medicine and Science, Rochester, MN, ³Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
Background/Purpose: SLE is an autoimmune disorder characterized by autoantibody-mediated tissue damage. Antibodies against C1q (anti-C1q) can identify patients with LN and rising titers predict renal…
Abstract Number: 1505 • ACR Convergence 2024
Incidence of Cardiovascular and Venous Thromboembolic Events in Four Autoantibody-defined Systemic Lupus Erythematosus Clusters
Sara Ferrigno¹, Elizabeth Arkema², Lina Marcela Diaz-Gallo³, Iva Gunnarsson⁴, Agneta Zickert⁴ and Elisabet Svenungsson⁵, ¹Department of Systems' Medicine, University of Rome Tor Vergata, Rome, Italy, ²Department of Medicine Solna, Clinical Epidemiology Division, Stockholm, Sweden, ³Center for Molecular Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ⁴Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ⁵Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Systemic lupus erythematosus (SLE) patients have higher cardiovascular (CV) risk compared to the general population, with a standardized CV mortality rate of 2-3 and…
Abstract Number: 1521 • ACR Convergence 2024
Contemporary Lupus Nephritis Treatment and Outcomes Among Patients with Systemic Lupus Erythematosus in the United States
Aakash Patel¹, Baijun Zhou², Hyon K. Choi³ and April Jorge¹, ¹Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital, Lexington, MA
Background/Purpose: Lupus nephritis (LN) is associated with excess morbidity and mortality, with prior studies finding a disproportionate impact on Black patients. We sought to determine…
Abstract Number: 1540 • ACR Convergence 2024
Project HOPE: HydrOxychloroquine Adherence ProjEct
Meredith LiCalzi¹, Fotios Koumpouras² and Jacinta Renaldi³, ¹Frank H. Netter MD School of Medicine at Quinnipiac University, North Haven, CT, ²Yale School of Medicine, New Haven, CT, ³Yale New Haven Hospital, New Haven, CT
Background/Purpose: Hydroxychloroquine (HCQ) is known to reduce flares, improve disease activity and mortality in patients with systemic lupus erythematosus (SLE).1 Nonadherence to HCQ is a noteworthy…
Abstract Number: 1649 • ACR Convergence 2024
B Cell Subset Contribution to Autoantibodies in Lupus
Kristina Ottens¹, Jalyn Schneider¹ and Anne Satterthwaite², ¹UT Southwestern Medical Center, Dallas, ²UT Southwestern Medical Center, Dallas, TX
Background/Purpose: Systemic lupus erythematous is characterized by the production of pathogenic autoantibodies that drive inflammation and tissue damage. Defining the B cell subsets that give…
Abstract Number: 1752 • ACR Convergence 2024
T Cell-Engaging Bispecific Antibodies to Target Autoreactive 9G4 Idiotope B Cells in Systemic Lupus Erythematosus
Jin Liu¹, Yuanxuan Xia¹, Dylan Ferris¹, Elana Shaw¹, Brian Mog¹, Alexander Pearlman¹, Brock Moritz¹, Kyle J. Kaeo¹, Colin Gliech¹, Tolulope Awosika¹, Sarah DiNapoli¹, Tushar Nichakawade¹, Yang Li¹, Jiaxin Ge¹, Stephanie Glavaris¹, Nikita Marcou¹, Taha Ahmedna¹, Regina Bugrovsky², Scott A. Jenks², Chetan Bettegowda¹, Daniel Goldman³, Michelle Petri³, Iñaki Sanz⁴, Kenneth W. Kinzler¹, Shibin Zhou¹, Bert Vogelstein¹, Suman Paul¹, Felipe Andrade⁵ and Maximilian F. Konig¹, ¹The Johns Hopkins University School of Medicine, Baltimore, MD, ²Emory University School of Medicine, Atlanta, GA, ³Johns Hopkins University School of Medicine, Timonium, MD, ⁴Emory University School of Medicine, Atlanta, ⁵The Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: Chimeric antigen receptor (CAR)-T-cell therapies hold promise for systemic lupus erythematosus (SLE) but are critically limited by scalability and long-term safety (e.g., risk of…
Abstract Number: 1792 • ACR Convergence 2024
CD14+ Monocytes Demonstrate Subclinical Erythrocyte Uptake in Childhood Onset Systemic Lupus Erythematosus
Lauren Robinson¹, Preetha Balasubramanian², Zurong Wan², Juan Rodriguez Alcazar², Marina Lima Silva Santos², Lynnette Walters³, Jeanine Baisch², Karen Onel⁴, Tracey Wright⁵, Virginia Pascual⁶ and Simone Caielli², ¹Hospital for Special Surgery, New York, NY, ²Weill Cornell Medicine, New York, NY, ³Scottish Rite Hospital for Children, Allen, TX, ⁴HSS, New York, NY, ⁵UT Southwestern, Plano, TX, ⁶Weill Cornell Medical College, New York, NY
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a disease characterized by the presence of auto-antibodies, immune complex deposition, and a robust type I interferon (IFN) signature.…
Abstract Number: 1812 • ACR Convergence 2024
Glycosylation Changes as Non-Invasive Biomarkers for Lupus Nephritis Detection and Prognosis
Aaron Angerstein¹, Richard Drake², Vishwajeeth Pasham², Bethany Wolf², Jim Oates² and Tammy Nowling², ¹Medical University of South Carolina, North Charleston, SC, ²Medical University of South Carolina, Charleston, SC
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease predominantly affecting women of childbearing age. Roughly 50% of SLE patients develop Lupus Nephritis (LN),…
Abstract Number: 2026 • ACR Convergence 2024
Cardiovascular Risk Measured by PREVENT Calculator and Disease Activity in Patients with Systemic Lupus Erythematosus
Rebeca L. Polina-Lugo¹, Aleydis Gonzalez Melendez¹, Maria F. Elizondo-Benitez², Andrea Guajardo Aldaco¹, Annette Dominguez-Guerra³, Victoria P. Limas-Martínez¹, Iris Jazmín Colunga Pedraza¹, Dionicio Galarza-Delgado⁴, jose Ramon Azpiri-Lopez⁵, Rosa Icela Arvizu-Rivera¹ and Jesus Cardenas-de la Garza⁶, ¹Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ²Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ³Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ⁴UANL Hospital Universitario, Monterrey, Nuevo León, Mexico, ⁵Division of Cardiology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ⁶Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico
Background/Purpose: Increased disease activity by SLEDAI (Systemic Erythematosus Lupus Disease Activity Index) has been associated with higher cardiovascular risk (CVR) and atherosclerotic cardiovascular disease (ASCVD),…
Abstract Number: 2376 • ACR Convergence 2024
Systemic Lupus Erythematosus Patients Exhibit Dynamic Changes in Disease-Associated Transcripts Following Total Knee or Total Hip Arthroplasty
David Fernandez¹, Stephen Batter¹, Deanna Jannat-Khah¹, Mikhail Olferiev¹, Insa Mannstadt², Mark Figgie¹, Peter Sculco¹, Jason Blevins¹, Caroline Siegel¹, Dina Greenman¹, Kyriakos Kirou¹ and Susan Goodman³, ¹Hospital for Special Surgery, New York, NY, ²Columbia University VP&S, New York, NY, ³Hospital for Special Surgery, New York 10025, NY
Background/Purpose: Patients with systemic lupus erythematosus (SLE) undergoing total hip arthroplasty and total knee arthroplasty (THA and TKA) experience higher complication rates than osteoarthritis (OA)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].